BM 15766 sulfate, > = 98% ( HPLC), poudre

Code: b8685-1mg D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Dehydrocholesterol reductase inhibitor. Inhibits 7-dehydrocholesterol reductase, which catalyzes the last step of cholesterol synthesis.


en savoir plus

Votre prix
£193.00 1MG

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Dehydrocholesterol reductase inhibitor. Inhibits 7-dehydrocholesterol reductase, which catalyzes the last step of cholesterol synthesis.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

1, 5 mg in glass bottle

assay≥98% (HPLC)
colorwhite
formpowder
InChI keyOVMQIVIYKXXEIT-UHFFFAOYSA-N
InChI1S/C22H25ClN2O2.H2O4S/c23-21-9-5-18(6-10-21)2-1-12-24-14-16-25(17-15-24)13-11-19-3-7-20(8-4-19)22(26)27;1-5(2,3)4/h1-10H,11-17H2,(H,26,27);(H2,1,2,3,4)
mp>300 °C
originatorRoche
Quality Level100
SMILES stringOS(O)(=O)=O.OC(=O)c1ccc(CCN2CCN(CC2)CC=Cc3ccc(Cl)cc3)cc1
solubilitywater: insoluble, DMSO: soluble 4 mg/mL
storage temp.2-8°C
Code
Description
Unité de vente
Prix annoncé
Qté
B8685-5MG
Unité:5MG
Prix annoncé: £728.00
Source:Prix annoncé
Cas Number86621-94-5
Ce produit répond aux critères suivants: